Atlanta Consulting Group Advisors’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.97M Buy
19,551
+7,522
+63% +$1.75M 0.79% 23
2026
Q1
$2.94M Buy
12,029
+424
+4% +$98.8K 0.63% 22
2025
Q4
$2.4M Sell
11,605
-192
-2% -$38K 0.54% 30
2025
Q3
$2.19M Buy
11,797
+1,014
+9% +$174K 0.54% 30
2025
Q2
$1.65M Sell
10,783
-103
-0.9% -$15.8K 0.45% 33
2025
Q1
$1.81M Sell
10,886
-275
-2% -$43K 0.53% 25
2024
Q4
$1.61M Sell
11,161
-3,118
-22% -$483K 0.6% 31
2024
Q3
$2.31M Buy
14,279
+3,341
+31% +$532K 0.57% 32
2024
Q2
$1.6M Buy
10,938
+106
+1% +$15.8K 0.34% 33
2024
Q1
$1.71M Buy
+10,832
New +$1.72M 0.59% 26

Other funds holding JNJ

Atlanta Consulting Group Advisors's JNJ Position: Q2 2026 in Review

Atlanta Consulting Group Advisors increased its Johnson & Johnson (JNJ) stake by 63% in Q2 2026, buying an estimated $1.75M and bringing the position to 19,551 shares worth $4.97M. The position accounts for 0.79% of the portfolio, ranked #23.

Atlanta Consulting Group Advisors first reported a position in JNJ in Q1 2024 and has held it in 10 quarters since. 4,665 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Atlanta Consulting Group Advisors held 19,551 shares of Johnson & Johnson worth $4.97M as of Q2 2026.
  • Atlanta Consulting Group Advisors bought 7,522 Johnson & Johnson shares in Q2 2026, an estimated $1.75M.
  • Johnson & Johnson made up 0.79% of Atlanta Consulting Group Advisors's portfolio in Q2 2026, its #23 holding.
  • Atlanta Consulting Group Advisors first reported a position in Johnson & Johnson in Q1 2024 and has held it in 10 quarters since.
  • 4,665 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Atlanta Consulting Group Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.